Therapeutic subgroup
D11 – ANDERE DERMATIKA
- Anatomical main group D: DERMATIKA
20Decisions
24Patient groups
Added benefit by patient group
- Considerable3
- Minor1
- Non-quantifiable4
- Not proven16
Subgroups
- D11A ANDERE DERMATIKA 20 decisions
Decisions, newest first
- 2025-08-07NemluvioNemolizumabNot proven
- 2025-08-07NemluvioNemolizumabNot proven
- 2025-05-15DupixentDupilumabNot proven
- 2025-04-03AnzupgoDelgocitinibNot proven: 2 of 2 patient groups
- 2025-02-06DupixentDupilumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-10-17CibinqoAbrocitinibNot proven
- 2024-06-06EbglyssLebrikizumabNot proven
- 2023-10-05DupixentDupilumabNon-quantifiable
- 2023-09-21DupixentDupilumabNot proven
- 2023-09-21DupixentDupilumabNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-05-12AdtralzaTralokinumabNot proven
- 2023-01-19AxhidroxGlycopyrroniumNot proven
- 2022-10-06DupixentDupilumabNot proven
- 2022-07-07CibinqoAbrocitinibConsiderable
- 2022-01-06AdtralzaTralokinumabNot proven
- 2021-07-01DupixentDupilumabNon-quantifiable
- 2020-05-14DupixentDupilumabConsiderable
- 2020-02-20DupixentDupilumabNon-quantifiable
- 2020-02-20DupixentDupilumabNot proven: 2 of 2 patient groups
- 2018-05-17DupixentDupilumabConsiderable
Data status: 2026-10-29